Inhaltsseite: Home

Tuesday, 6 February 2024
Reading time : 2 minutes
Investment Ideas - Yield Enhancement

US Big Tech Has Little Room For Error

The air is getting thinner for US technology titans. After last year's stock price rally, investors expect nothing less than perfection from the «Magnificent Seven», as a review of the quarterly results reveals.

Thursday, 1 February 2024
Reading time : 2 minutes
Investment Ideas - Yield Enhancement

Sandoz: Betting On Biosimilars

About four months ago, Sandoz was spun off from its parent company Novartis. The success of the Swiss drugmaker is likely to be determined by its performance in the growing biosimilars market.

Tuesday, 30 January 2024
Reading time : 2 minutes
Investment Ideas - Yield Enhancement

Lonza Regains Confidence

After a difficult few months, Lonza shares have made a brilliant start to the new year.

Friday, 26 January 2024
Reading time : 2 minutes
Yield Enhancement

Tesla Shares Take A Dive

Tesla's disappointing quarterly results put pressure on the shares of the electric car manufacturer.

Monday, 22 January 2024
Reading time : 1 minute
Monday, 22 January 2024
Reading time : 3 minutes
Investment Ideas - Yield Enhancement

US Earnings Season Enters Full Swing

In the coming days and weeks, Wall Street will be monitoring company results closely. The «Magnificent Seven» are likely to attract particular attention as their shares have risen sharply in 2023.

Monday, 15 January 2024
Reading time : 2 minutes
Tuesday, 9 January 2024
Reading time : 2 minutes
Investment Ideas - Yield Enhancement

Reverse Convertibles On Equity Top Picks 2024

«ZKB Favourite Stocks 2024»: Building Exposure with Reverse Convertibles

Monday, 18 December 2023
Reading time : 2 minutes
Yield Enhancement

Stock Markets Enter The Final Round

A few trading days remain until the end of the year. After the loss-making previous year, the Swiss Market Index is set to post a positive performance.

Tuesday, 12 December 2023
Reading time : 2 minutes
Investment Ideas - Yield Enhancement

Turning Point For Roche?

The shares of Basel-based pharmaceutical group Roche remain a source of concern for investors this year. We think the outlook for 2024 is slightly better. However, the shares remain exposed to risk.


Ajax loading